In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 3, 2009, Pages 283-288

  Szabó, Zsuzsa ^a,b   Szilágyi, Judit ^b   Tavanti, Ariana ^c   Kardos, Gábor ^b   Rozgonyi, Ferenc ^a   Bayegan, Sedique ^b   Majoros, László ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

"Psilosis group"; Amphotericin B; Killing curves; Triazole antifungals

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DRUG EFFICACY; FUNGICIDAL ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TIME FACTORS;

EID: 67349110395     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.03.011     Document Type: Article

References (14)

1. Cantón E., Pemán J., Gobernado M., Viudes A., and Espinel-Ingroff A. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48 (2004) 2477-2482
2. Gomez-Lopez A., Alastruey-Izquierdo A., Rodriguez D., Almirante B., Pahissa A., Rodriguez-Tudela J.L., Cuenca-Estrella M., and the Barcelona Candidemia Project Study Group. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob. Agents Chemother. 52 (2008) 1506-1509
3. Klepser M.E., Ernst E.J., Lewis R.E., Ernst M.E., and Pfaller M.A. Influence of test conditions on antifungal time-kill curve results for standardized methods. Antimicrob. Agents Chemother. 42 (1998) 1207-1212
4. Lewis R.E., and Wiederhold N.P. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. Clin. Infect. Dis. 37 (2003) 871-872
5. Lockhart S.R., Messer S.A., Pfaller M.A., and Diekema D.J. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis, in comparison to the closely-related species Candida parapsilosis. J. Clin. Microbiol. 46 (2008) 2659-2664
6. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - second edition, M27-A2. Wayne, PA:NCCLS. 2nd ed. (2002), NCCLS, Wayne, PA
7. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kullberg B.J., Ostrosky-Zeichner L., Reboli A.C., Rex J.H., Walsh T.J., and Sobel J.D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (2009) 503-535
8. Pfaller M.A., Boyken L., Messer S.A., Tendolkar S., Hollis R.J., and Diekema D.J. Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J. Clin. Microbiol. 42 (2004) 4977-4979
9. Pfaller M.A., Diekema D.J., and Sheehan D.J. Interpretative breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19 (2006) 435-447
10. Sóczó G., Kardos G., McNicholas P.M., Balogh E., Gergely L., Varga I., Kelentey B., and Majoros L. Correlation of posaconazole minimum fungicidal concentration and time-kill test against nine Candida species. J. Antimicrob. Chemother. 60 (2007) 1004-1009
11. Tavanti A., Davidson A.D., Gow N.A.R., Maiden M.C., and Odds F.C. Candida orthopsilosis and Candida metapsilosis spp. nov., to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43 (2005) 284-292
12. Tavanti A., Hensgens L.A.M., Ghelardi E Campa M., and Senesi S. Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J. Clin. Microbiol. 45 (2007) 1455-1462
13. van Asbeck E., Clemons K.V., Martinez M., Tong A.J., and Stevens D. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn. Microbiol. Infect. Dis. 62 (2008) 106-109
14. Varga I., Sóczó G., Kardos G., Borbély A., Szabó Z., Kemény-Beke A., and Majoros L. Comparison of killing activity of caspofungin against Candida parapsilosis, C. orthopsilosis and C. metapsilosis. J. Antimicrob. Chemother. 62 (2008) 1466-1468